1-3 of 3
Sara Ferrando-Martínez
Close
Sort by
Journal Articles

A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

Armin Ghobadi, L. Elizabeth Budde, Ahmed Galal, Kristina Stermer, Allison Bierly, Sara Ferrando-Martinez, Byung Ha Lee, John F. DiPersio
Journal: Blood
Blood (2022) 140 (Supplement 1): 10366–10367.
https://doi.org/10.1182/blood-2022-159504
Published: 2022
Journal Articles

Potential Synergy of TRAIL with CDK9 Inhibition in Selective Killing of HIV Infected Cell Lines and Primary CD4+ T Cells

David Kotlyar, MD, Constantinos Petrovas, PhD, Arik Cooper, PhD, David Ambrozak, MS, Christina Annunziata, MD PhD, Lidia Hernandez, PhD, Takuya Yamamoto, PhD, Sara Ferrando-Martinez, PhD, Joseph Casazza, MD PhD, Richard Koup, MD
Journal: Blood
Blood (2014) 124 (21): 4142.
https://doi.org/10.1182/blood.V124.21.4142.4142
Published: 2014
Journal Articles

CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection

Rodolfo Silva, Susan Moir, Lela Kardava, Karen Debell, Venkateswara R. Simhadri, Sara Ferrando-Martínez, Manuel Leal, José Peña, John E. Coligan, Francisco Borrego
Journal: Blood
Blood (2011) 117 (22): 5870–5880.
https://doi.org/10.1182/blood-2010-09-310318
Published: 2011
Includes: Supplemental data